The customer observed falsely elevated architect free t4 results on a patient diagnosed with hypothyroidism.The following data was provided: on (b)(6) 2023.Tsh 1.65, ft3 2.41, ft4 1.42.Sid (b)(6) , on (b)(6) 2024 , initial test, repeat test, tsh 2.8109 uiu/ml, 3.5787 uiu/ml, ft3 2.84 pg/ml, 2.33 pg/ml, ft4 >5.00 ng/dl, 1.95 ng/dl.Sid (b)(6), on (b)(6) 2024, initial test, repeat test, ft4 >5.00 ng/dl, 0.96 ng/dl.Sid (b)(6), on (b)(6) 2024, initial test, repeat test, ft4 2.05 ng/dl, 1.18 ng/dl.No impact to patient management was reported.
|
Data and information provided by the customer were reviewed and align with the complaint issue and no additional issues were identified.The ticket search by lot indicates that the reagent lot shows elevated complaint activity, however, in-house performance testing was completed which indicates the product is performing as expected.Device history review did not identify any non-conformances or deviations with the complaint list number.A review of ticket trending did not identify any related trend regarding commonalities for complaint lot number and issue.Retained analysis of architect free t4 reagent lot 56001ud00 was performed.Testing met acceptance criteria and the product is performing as expected.A review of the labelling addresses the customer¿s issue.Based on the investigation, no systemic issue or deficiency of the architect free t4 assay was identified.
|